Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

More than half of human colorectal cancers (CRCs) carry either KRAS or BRAF mutations and are often refractory to approved targeted therapies.We found that cultured human CRC cells harboring KRAS or BRAFmutations are selectively killed when exposed to high levels of Vitamin C. This effect is due to increased uptake of the oxidized form of Vitamin C, dehydroascorbate (DHA), via the GLUT1 glucose transporter. Increased DHA uptake causes oxidative stress as intracellular DHA is reduced to Vitamin C, depleting glutathione.Thus, reactive oxygen species accumulate and inactivate glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Inhibition of GAPDH in highly glycolytic KRAS or BRAF mutant cells leads to an energetic crisis and cell death not seen in KRAS and BRAF wild-type cells. High-dose Vitamin C impairs tumor growth in Apc/KrasG12D mutant mice.These results provide a mechanistic rationale for exploring the therapeutic use of Vitamin C for CRCs with KRAS or BRAF mutations.

Original publication

DOI

10.1126/science.aaa5004

Type

Journal article

Journal

Science

Publication Date

11/12/2015

Volume

350

Pages

1391 - 1396